PT-141

PT-141 (Bremelanotide) is a synthetic peptide developed from Melanotan II that is primarily used for treating sexual dysfunction in both men (erectile dysfunction) and women (hypoactive sexual desire disorder). Unlike other sexual dysfunction medications (like Viagra/Cialis) that target the vascular system, PT-141 works centrally by activating melanocortin receptors (MC3-R and MC4-R) in the hypothalamus to directly increase sexual desire and arousal. It is FDA-approved (as Vyleesi) for premenopausal women. It is effective for both physiological and psychological sexual dysfunction.

Administer 1–2 mg subcutaneously approximately 45 minutes to 1 hour before anticipated sexual activity. Start with a lower dose (1 mg) to assess tolerance, as nausea is a common side effect. Do not exceed one dose per 24 hours or 8 doses per month. Effects can last up to 24 hours.